HeXun Biosciences Co (ROCO:6986) Shares Outstanding (EOP): 52.1 Mil (As of Dec. 2025)


ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
23 GF Score
Price NT$47.00
! 1 Warning Sign
View Full Analysis

What is HeXun Biosciences Co Shares Outstanding (EOP)?

HeXun Biosciences Co ROCO:6986 23 Shares Outstanding (EOP) is 52.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. HeXun Biosciences Co's shares outstanding for the quarter that ended in Dec. 2025 was 52.1 Mil.

HeXun Biosciences Co's quarterly shares outstanding increased from Sep. 2025 (46.8 Mil) to Dec. 2025 (52.1 Mil). It means HeXun Biosciences Co issued new shares from Sep. 2025 to Dec. 2025 .

HeXun Biosciences Co's annual shares outstanding increased from Dec. 2024 (46.0 Mil) to Dec. 2025 (52.1 Mil). It means HeXun Biosciences Co issued new shares from Dec. 2024 to Dec. 2025 .


HeXun Biosciences Co  (ROCO:6986) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


HeXun Biosciences Co Shares Outstanding (EOP) Related Terms


HeXun Biosciences Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Shares Outstanding (EOP) Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 46.00 46.00 46.00 46.00 52.13

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 46.00 46.00 46.00 46.79 52.13

ROCO:6986 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, HeXun Biosciences Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeXun Biosciences Co Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where HeXun Biosciences Co's Shares Outstanding (EOP) falls into.


ROCO:6986
23GF Score
HeXun Biosciences Co Ltd ROCO:6986
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 52.1 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Shares Outstanding (EOP) of 52.1 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Shares Outstanding (EOP) too high?
HeXun Biosciences Co's current Shares Outstanding (EOP) is 52.1 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Shares Outstanding (EOP) compare to VRTX and REGN?
HeXun Biosciences Co's Shares Outstanding (EOP) of 52.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Shares Outstanding (EOP) is 52.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Shares Outstanding (EOP) of 52.1 Mil. The current Shares Outstanding (EOP) is 52.1 Mil. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Shares Outstanding (EOP) is 52.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score

Get the complete analysis for ROCO:6986

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.00
Price